Humanigen bet everything on lenzilumab becoming the cytokine-storm drug that saved COVID patients — the FDA said no in June 2021, and the company filed for Chapter 11 in January 2022.
Evaluating only Humanigen’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Key Events Timeline
FOUNDING
Humanigen founded
LAYOFF
Market downturn forces cuts
SHUTDOWN
Bankruptcy: Humanigen ceases operations
Full Analysis
Free · no account needed
Documented cause
Humanigen developed lenzilumab, an antibody targeting GM-CSF to block the cytokine storm that killed severe COVID patients. Its Phase 3 trial showed a trend toward benefit but missed statistical significance. The FDA declined to grant Emergency Use Authorization in June 2021, citing insufficient evidence of benefit. With no approved indication and no pipeline to fall back on, the company exhausted its remaining cash and filed for Chapter 11 in January 2022.
Lesson
“Companies built around a single COVID-indication bet have no fallback if that EUA is denied — pipeline diversification is not optional when regulatory outcomes are binary.”